Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDKN1B
REST API REST API
Homo sapiens
CDKN1B is differentially expressed in 281 experiments: 89 organism parts: cerebellum, amygdala, ... (87 more);, 159 disease states: normal, control, ... (157 more);, 82 cell types 347 cell lines 47 compound treatments and 71 other conditions.
Synonyms P27KIP1, KIP1
Orthologs cdkn1b (Danio rerio)   CDKN1B (Gallus gallus)   CDKN1B (1 of 3) (Danio rerio)   cdkn1bl (Danio rerio)   Cdkn1b (Mus musculus)   A6QLS3_BOVIN (Bos taurus)   Cdkn1b (Rattus norvegicus)   CDN1B_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cyclin-dependent protein kinase activity, cytosol, negative regulation of cell growth, phosphorylation, negative regulation of transcription, DNA-dependent, protein binding, cytoplasm, negative regulation of cell proliferation, positive regulation of cell proliferation, autophagic cell death, mitotic cell cycle, regulation of cyclin-dependent protein kinase activity, negative regulation of apoptosis, cell cycle arrest, potassium ion transport, G1 phase of mitotic cell cycle, fibroblast growth factor receptor signaling pathway, induction of apoptosis, cell cycle, sensory perception of sound, G1/S transition of mitotic cell cycle, nucleus, positive regulation of microtubule polymerization, kinase activity, endosome, nucleoplasm, cell cycle checkpoint, S phase of mitotic cell cycle, cyclin-dependent protein kinase inhibitor activity, negative regulation of epithelial cell proliferation, negative regulation of cyclin-dependent protein kinase activity, DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest, negative regulation of epithelial cell proliferation involved in prostate gland development, negative regulation of kinase activity, negative regulation of cellular component movement, positive regulation of protein catabolic process, inner ear development, protein kinase inhibitor activity, cellular response to lithium ion, cellular response to antibiotic, negative regulation of phosphorylation, nerve growth factor receptor signaling pathway, protein phosphatase binding, transforming growth factor beta receptor, cytoplasmic mediator activity, phosphatidylinositol-mediated signaling, cellular response to organic cyclic compound
InterPro Term CDI
UniProt Accession P46527, Q9UH60, Q6I9V6, B4DPH2, E7ES52
Gene-Disease Assocation MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV; MEN4
Search EB-eye ENSG00000111276
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-7224, E-MEXP-433, E-GEOD-7540, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (34 experiments)

Factor Value U/D Experiments
HeLa
2
E-GEOD-5823, E-MTAB-62
DU145
2
E-GEOD-17482, E-GEOD-20089
T84
2
E-MTAB-37, E-GEOD-1474
SW480
1
2
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
BT474
1
2
E-MEXP-440, E-MTAB-37, E-MTAB-62
NA19119
1
E-GEOD-19480
341 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (44 experiments)

Factor Value U/D Experiments
epithelial cell
2
E-MEXP-2034, E-GEOD-10797
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
bronchial epithelial
2
E-AFMX-5, E-MTAB-25
fibroblast
2
E-GEOD-3920, E-GEOD-3204
testis - leydig cell
2
E-AFMX-5, E-TABM-145
CD8+ T cell
1
2
E-AFMX-5, E-GEOD-6740, E-TABM-145
76 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, ... (50 experiments)

Factor Value U/D Experiments
control
1
2
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363
NC-NC lymphoblastoid B cell line
1
E-MTAB-62
Mantle cell lymphoma
1
E-GEOD-18736
chronic myelogenous leukemia
1
E-GEOD-5550
juvenile idiopathic arthritis subtype oligoarthritis
1
E-GEOD-13501
LF (follicular lymphoma)
1
E-GEOD-16455
153 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-697, E-TABM-782, E-GEOD-3720, ... (29 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-20719, E-GEOD-412, E-MEXP-1958, E-MEXP-2285, E-GEOD-5824, ... (9 experiments)
sapphyrin PCI-2052
1
E-GEOD-6400
sapphyrin PCI-2054
1
E-GEOD-6400
selenium
1
E-MEXP-1327
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
CNOT7+CNOT8
1
E-MEXP-2218
41 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-GEOD-860, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-1751, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-TABM-763, E-GEOD-1923, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-1446, E-GEOD-9764, E-GEOD-10315, E-GEOD-837, ... (9 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-MEXP-561

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-2487, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, ... (10 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.36 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM